N-hydroxy-3-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl) benzamide | 1429652-59-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-hydroxy-3-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl) benzamide
• 英文别名: N-hydroxy-3-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl)benzamide；N-hydroxy-3-[2-[N-(2-hydroxyethyl)anilino]-2-oxoethyl]benzamide
• CAS: 1429652-59-4
• 化学式: C₁₇H₁₈N₂O₄
• 分子量: 314.341
• InChiKey: MSFDDWNQFRLDNL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1
• 重原子数：
  23
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  89.9
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  N-苯基乙醇胺 在 咪唑 、 盐酸 、 potassium cyanide 、 羟胺 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 、 二氯甲烷 为溶剂， 反应 34.0h， 生成 N-hydroxy-3-(2-((2-hydroxyethyl)(phenyl)amino)-2-oxoethyl) benzamide
  参考文献：
  名称：

  [EN] NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE 1
  [FR] NOUVELLES MOLÉCULES QUI INHIBENT SÉLECTIVEMENT L'HISTONE-DÉACÉTYLASE 6 PAR RAPPORT À L'HISTONE-DÉACÉTYLASE 1

  摘要：

  本发明的化合物是HDAC6选择性抑制剂，其基于乙酰化微管蛋白的积累而被识别，而不是乙酰化组蛋白的积累。组蛋白去乙酰化酶或“HDAC”指的是能够从蛋白质（包括组蛋白和微管蛋白）中切除乙酰基（-C(=0)CH3）的酶。还公开了包含这些分子的组合物以及用于抑制组蛋白去乙酰化酶活性的方法，包括用于治疗的方法。

  公开号：

  WO2013052110A1

文献信息

• NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE 1
  申请人：The Trustees of Columbia University in the City of New York

  公开号：US20140288119A1

  公开（公告）日：2014-09-25

  This invention provides a compound having the structure: wherein R 1 is H, halogen, —NR 5 R 6 , —NR 5 —C(═O)—R 6 , —NH—C(═O)—OR 7 , —OR 7 , —NO 2 , —CN, —SR 7 , —SO 2 R 7 , —CO 2 R 7 , CF 3 , —SOR 7 , —POR 7 , —C(═S)R 7 , —C(═O)—NR 5 R 6 , —CH 2 —C(═O)—NR 5 R 6 , —C(═NR 5 )R 6 , —P(═O)(OR 5 )(OR 6 ), —P(OR 5 )(OR 6 ), —C(═S)R 7 , C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, aryl, heteroaryl, or heterocyclyl, wherein R 5 , R 6 , and R 7 and are each, independently, H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m is an integer from 0 to 2; R 2 and R 3 are each, independently, H, halogen, —NH 2 , —CX 3 , —C(═O)OR 8 , C(═O)R 8 , —C(═O)NR 9 R 10 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroalkyl, aryl, heteroaryl, or heterocyclyl; wherein X is Cl, Br, or F; R 8 , R 9 and R 10 are each, independently, H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Q is —Ar 1 —Z— or —Z—Ar 1 —Z—, wherein Ar 1 is aryl or heteroaryl; and each occurrence of Z is independently present or absent, and when present is —O—, —S—, —CH 2 —, —C(O)— —NH—, —NH—NH—, —NHC(═O)—, —C(═O)NH—, —NHC(═O)CH 2 NH—, —NHC(═O)CH 2 C(═O)—, —N(OH)—, —CH 2 CH 2 — or —NHC(═O)CH═CH—; and R 4 is alkyl, —OR 11 or —NH—OR 11 , wherein R 11 is H, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, heteroaryl, or heterocyclyl, and when Q is —Ar 1 —Z—, Z is absent, Ar 1 is phenyl, R 2 and R 3 are H, n=1, and R 4 is —NHOH, then R 1 is other than carbazole, tetrahydro-β-carboline, tetrahydro-γ-carboline, —C(═O)—NR 5 R 6 and —NR 5 —C(═O)—R 6 , wherein one of R 5 or R 6 is quinoline and the other of R 5 or R 6 is H; or a pharmaceutically acceptable salt thereof.

  该发明提供了一种具有以下结构的化合物：其中，R1为H、卤素、—NR5R6、—NR5—C(═O)—R6、—NH—C(═O)—OR7、—OR7、—NO2、—CN、—SR7、—SO2R7、—CO2R7、CF3、—SOR7、—POR7、—C(═S)R7、—C(═O)—NR5R6、—CH2—C(═O)—NR5R6、—C(═NR5)R6、—P(═O)(OR5)(OR6)、—P(OR5)(OR6)、—C(═S)R7、C1-5烷基、C2-5烯基、C2-5炔基、芳基、杂芳基或杂环烷基，其中，R5、R6和R7各自独立地为H、C1-5烷基、C2-5烯基、C2-5炔基、杂基、环烷基、杂环烷基、芳基或杂芳基；m为0到2的整数；R2和R3各自独立地为H、卤素、—NH2、—CX3、—C(═O)OR8、C(═O)R8、—C(═O)NR9R10、C1-10烷基、C2-10烯基、C2-10炔基、杂基、芳基、杂芳基或杂环烷基，其中，X为Cl、Br或F；R8、R9和R10各自独立地为H、C1-5烷基、C2-5烯基、C2-5炔基、杂基、环烷基、杂环烷基、芳基或杂芳基；Q为—Ar1—Z—或—Z—Ar1—Z—，其中，Ar1为芳基或杂芳基；Z的每次出现都是独立存在或缺失的，当存在时为—O—、—S—、— —、—C(O)——NH—、—NH—NH—、—NHC(═O)—、—C(═O)NH—、—NHC(═O) NH—、—NHC(═O) C(═O)—、—N(OH)—、— —或—NHC(═O)CH═CH—；R4为烷基、—OR11或—NH—OR11，其中，R11为H、C1-10烷基、C2-10烯基、C2-10炔基、芳基、杂芳基或杂环烷基，当Q为—Ar1—Z—，Z不存在，Ar1为苯基，R2和R3为H，n=1，且R4为—NHOH时，R1不是咔唑、四氢-β-咔啉、四氢-γ-咔啉、—C(═O)—NR5R6和—NR5—C(═O)—R6，其中R5或R6之一为喹啉，另一个为H；或其药学上可接受的盐。
• NOVEL MOLECULES THAT SELECTIVELY INHIBIT HISTONE DEACETYLASE 6 RELATIVE TO HISTONE DEACETYLASE
  申请人：Breslow Ronald

  公开号：US20170066712A1

  公开（公告）日：2017-03-09

  This invention provides a compound having the structure: wherein R 1 is H, halogen, —NR 5 R 6 , —NR 5 —C(═0)-R 6 , —NH—C(═O)—OR 7 , —OR 7 , —NO 2 , —CN, —SR 7 , —SO 2 R 7 , —CO 2 R 7 , CF 3 , —SOR 7 , —POR 7 , —C(═S)R 7 , —C(═O)—NR 5 R 6 , —CH 2 —C(═O)—NR 5 R 6 , —C(═NR 5 )R 6 , —P(═O)(OR 5 )(OR 6 ), —P(OR 5 )(OR 6 ), —C(═S)R 7 , C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, aryl, heteroaryl, or heterocyclyl, wherein R 5 , R 6 , and R 7 and are each, independently, H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; m is an integer from 0 to 2; R 2 and R 3 are each, independently, H, halogen, —NH 2 , —CX 3 , —C(═O)OR 8 , C(═O)R 8 , —C(═O)NR 9 R 10 , C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, heteroalkyl, aryl, heteroaryl, or heterocyclyl; wherein X is Cl, Br, or F; R 8 , R 9 and R 10 are each, independently, H, C 1-5 alkyl, C 2-5 alkenyl, C 2-5 alkynyl, heteroalkyl, cycloalkyl, heterocycloalkyl, aryl, or heteroaryl; Q is —Ar 1 —Z— or —Z—Ar 1 —Z—, wherein Ar 1 is aryl or heteroaryl; and each occurrence of Z is independently present or absent, and when present is —O—, —S—, —CH 2 —, —C(O)—, —NH—, —NH—NH—, —NHC(═O)—, —C(═O)NH—, —NHC(═O)CH 2 NH—, —NHC(═O)CH 2 C(═O)—, —N(OH)—, —CH 2 CH 2 — or —NHC(═O)CH═CH—; and R 4 is alkyl, —OR 11 or —NH—OR 11 , wherein R 11 is H, C 1-10 alkyl, C 2-10 alkenyl, C 2-10 alkynyl, aryl, heteroaryl, or heterocyclyl, and when Q is —Ar 1 —Z—, Z is absent, Ar 1 is phenyl, R 2 and R 3 are H, n=1, and R 4 is —NHOH, then R 1 is other than carbazole, tetrahydro-β-carboline, tetrahydro-γ-carboline, —C(═O)—NR 5 R 6 and —NR 5 —C(═0)-R 6 , wherein one of R 5 or R 6 is quinline and the other of R 5 or R 6 is H; or a pharmaceutically acceptable salt thereof.
• US9499479B2
  申请人：——

  公开号：US9499479B2

  公开（公告）日：2016-11-22